<DOC>
	<DOCNO>NCT01075802</DOCNO>
	<brief_summary>Tamoxifen important drug treatment breast cancer . Used adjuvantly operation early breast cancer , tamoxifen reduces annual recurrence rate half cancer death one third . Used preventatively also reduce risk breast cancer 50 % woman high risk develop disease Tamoxifen need activate body active form call endoxifen , mainly enzyme call CYP2D6 . Patients variable capability activate tamoxifen due variable function enzyme . Studies show clear correlation specific genetic variant CYP2D6 endoxifen blood level . It estimate 25 % Caucasian population reduce even absent CYP2D6 function . More recently , study show correlation genetic variant CYP2D6 breast cancer relapse early breast cancer patient treat tamoxifen . Food Drug Authority ( FDA ) America recommend check CYP2D6 genotype patient receive tamoxifen treatment , specify interpret genotype result kind action take patient adverse genotype . The aim investigator study see increase tamoxifen patient genetic polymorphism CYP2D6 increase endoxifen level range patient wild type ( normal functional ) CYP2D6 .</brief_summary>
	<brief_title>Study Tamoxifen Dose Escalation Breast Cancer Patients With CYP2D6 Polymorphisms</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>ECOG performance status ≤ 1 Life expectancy ≥ 6 month Histologically cytologically confirm early , locally advanced metastatic breast cancer Oestrogen receptor positive About start tamoxifen treatment already tamoxifen 20mg daily Adequate hepatic renal function Concurrent chemotherapy radiotherapy Treatment medication may alter cytochrome P450 ( CYP450 ) 3A4/5 CYP2D6 activity History thrombosis History noncompliance previous current treatment ; Medical psychiatric condition compromise patient 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Endoxifen</keyword>
	<keyword>polymorphism CYP2D6</keyword>
</DOC>